Health Economics›Waldenstroem macroglobulinemia›First-line therapy non-randomized or retrospective data

First-line therapy non-randomized or retrospective data

Waldenstroem macroglobulinemia · 12 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 4 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Thalidomide and Rituximab Variant #01	—	R 265 626	28d	—	—	~12	~R 632 638 indirect	—
CaRD Variant #01	—	R 158 023	56d	—	—	~6	~R 691 033 indirect	—
FCR Variant #07	—	R 120 349	30d	~56.4 mo	—	~5	~R 361 047 PFS proxy · indirect	10
IDR Variant #01	—	R 117 991	56d	—	—	~6	~R 656 136 indirect	—
PCR Variant #03 Partial	—	R 103 769	28d	—	—	~6	~R 208 140 indirect	—
BDR Variant #01	—	R 66 028	21d	—	—	~4	~R 264 111 indirect	—
Bortezomib and Rituximab (VR) Variant #01	—	R 58 571	60d	~12.8 mo	—	~5	~R 241 048 PFS proxy · indirect	1
Cladribine and Rituximab Variant #01	—	R 48 077	21d	—	—	~6	~R 288 462 indirect	—
Fludarabine and Rituximab (FR) Variant #01	—	R 34 157	28d	—	—	~6	~R 204 943 indirect	—
Everolimus monotherapy Variant #01	—	R 18 360	28d	~6.0 mo	~18.1 mo	~2	~R 36 719 PFS proxy · indirect	15
Fludarabine monotherapy Variant #05	—	R 13 754	28d	~16.5 mo	~52.9 mo	~12	~R 165 047 PFS proxy · indirect	4
Thioguanine monotherapy Variant #01	—	R 6 994	28d	—	—	~2	~R 13 987 indirect	—

12 of 12 regimens shown